Hunan Er Kang Pharmaceutical Strategic Asset Allocation Index
Hunan Er Kang Pharmaceutical strategic asset allocation index. Hunan Er Kang Pharmaceutical (300267) has a Strategic Asset Allocation Index of 57.3% as of June 2023. Strategic assets (PP&E of CN¥2.92 Billion plus long-term investments of CN¥-) total CN¥2.92 Billion, measured against net assets of CN¥5.09 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See Hunan Er Kang Pharmaceutical net asset quality index to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Strategic Asset Allocation Index of Hunan Er Kang Pharmaceutical (2008–2022)
Strategic asset allocation index of Hunan Er Kang Pharmaceutical from 2008 to 2022. This chart shows how Hunan Er Kang Pharmaceutical's Strategic Asset Allocation Index has evolved across 15 annual periods from 2008 to 2022. As of June 2023, the index stands at 57.3%, representing strategic assets of CN¥2.92 Billion against net assets of CN¥5.09 Billion CNY. Check Hunan Er Kang Pharmaceutical (300267) tangible equity ratio to evaluate the tangible quality of the company's equity base.
Hunan Er Kang Pharmaceutical Strategic Asset Allocation Index by Year (2008–2022)
Hunan Er Kang Pharmaceutical strategic asset allocation index by year from 2008 to 2022. The table below presents the year-by-year Strategic Asset Allocation Index for Hunan Er Kang Pharmaceutical from 2008 to 2022, covering 15 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see 300267 stock market capitalisation.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 56.6% | CN¥2.86 Billion | CN¥2.86 Billion | CN¥- | CN¥5.05 Billion | ▲ +3.1 pp |
| 2021 | 53.4% | CN¥2.60 Billion | CN¥2.60 Billion | CN¥- | CN¥4.87 Billion | ▲ +2.4 pp |
| 2020 | 51.1% | CN¥2.96 Billion | CN¥2.96 Billion | CN¥- | CN¥5.79 Billion | ▲ +4.0 pp |
| 2019 | 47.1% | CN¥2.73 Billion | CN¥2.73 Billion | CN¥- | CN¥5.79 Billion | ▲ +1.2 pp |
| 2018 | 45.8% | CN¥2.59 Billion | CN¥2.59 Billion | CN¥- | CN¥5.64 Billion | ▼ -1.8 pp |
| 2017 | 47.7% | CN¥2.58 Billion | CN¥2.58 Billion | CN¥- | CN¥5.41 Billion | ▼ -0.8 pp |
| 2016 | 48.4% | CN¥2.54 Billion | CN¥2.54 Billion | CN¥- | CN¥5.24 Billion | ▲ +13.8 pp |
| 2015 | 34.6% | CN¥1.47 Billion | CN¥1.47 Billion | CN¥- | CN¥4.26 Billion | ▼ -24.8 pp |
| 2014 | 59.4% | CN¥996.61 Million | CN¥996.61 Million | CN¥- | CN¥1.68 Billion | ▲ +21.2 pp |
| 2013 | 38.2% | CN¥509.24 Million | CN¥509.24 Million | CN¥- | CN¥1.33 Billion | ▲ +8.5 pp |
| 2012 | 29.6% | CN¥345.15 Million | CN¥345.15 Million | CN¥- | CN¥1.16 Billion | ▲ +13.9 pp |
| 2011 | 15.7% | CN¥166.94 Million | CN¥166.94 Million | CN¥- | CN¥1.06 Billion | ▼ -54.2 pp |
| 2010 | 69.9% | CN¥123.48 Million | CN¥123.48 Million | CN¥- | CN¥176.62 Million | ▲ +12.7 pp |
| 2009 | 57.2% | CN¥62.89 Million | CN¥62.89 Million | CN¥- | CN¥110.01 Million | ▼ -25.2 pp |
| 2008 | 82.4% | CN¥51.91 Million | CN¥51.91 Million | CN¥- | CN¥63.01 Million | — |